Medical AI

A new partnership is challenging the supplement status quo with a creatine product that targets brain energy, not just brawn, for a new era in women's health.

A new clinical trial for a sacroiliac joint device isn't just about technology; it's about a company's bet that rigorous evidence is the best medicine for patients and the healthcare system.

A Cambridge startup is building a 'Common Crawl for the living world,' framing biological data as a strategic weapon in the US-China tech rivalry.

A new Philips report quantifies AI's benefits in healthcare, from saving time to catching errors. But the path to adoption is fraught with challenges.

AI is poised to revolutionize medicine, but 'hallucinations' pose a grave risk. Experts are now engineering new safeguards to ensure AI helps, not harms.

A new medical AI, trained on vast proprietary data, is now live in a US clinic. It reasons like a physician, not a scribe, setting a new bar for trust and accuracy.

Johnson & Johnson's acquisition of Firefly Bio for $1 billion signals a major push into degrader antibody conjugates, a new frontier for treating KRAS cancers.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

New trial data shows Sequel Med Tech's twiist™ AID system could bring much-needed simplicity and safety to millions with insulin-treated type 2 diabetes.

Portable oxygen offers freedom, but as companies market summer travel, a closer look reveals that not all devices may deliver on their life-sustaining promise.

Sleep is now a bankable asset. A new wave of research is changing how high-stakes industries like aviation manage fatigue, turning rest into a strategic advantage.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

The federal government hails its new AI strategy as 'pro-worker,' but a major public service union warns it lacks crucial safeguards, risking jobs and services.

With key regulatory decisions pending in Canada and the US, DIAGNOS's CARA AI platform is set to unlock a multi-billion dollar market for early eye disease detection.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A new partnership aims to revolutionize battery safety by sniffing out fires before they start. But can this defense-grade tech scale for our battery-powered world?

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

Senté renewed its pact with a top scientist. We explore how deep scientific partnerships are becoming the key differentiator in a crowded, hype-filled market.

Swedish innovator Triomed AB unveils a system that triples ultrafiltration in peritoneal dialysis, tackling a critical patient risk and challenging market leaders.

The 3rd annual National STEM Festival brings PhD-level student research to D.C., connecting young builders with leaders to solve real-world workforce shortages.